Related references
Note: Only part of the references are listed.Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
International Myeloma Working Group recommendations for global myeloma care
H. Ludwig et al.
LEUKEMIA (2014)
The current status of minimal residual disease assessment in myeloma
S. K. Kumar et al.
LEUKEMIA (2014)
An overview of the progress in the treatment of multiple myeloma
Robert A. Kyle et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
New Strategies in the Treatment of Multiple Myeloma
Nikhil C. Munshi et al.
CLINICAL CANCER RESEARCH (2013)
Initial treatment of multiple myeloma
S. Vincent Rajkumar
HEMATOLOGICAL ONCOLOGY (2013)
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Maria-Victoria Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A gene expression signature for high-risk multiple myeloma
R. Kuiper et al.
LEUKEMIA (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Nikhil C. Munshi et al.
BLOOD (2011)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Dimopoulos et al.
BLOOD (2011)
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
Jerome Moreaux et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Multidimensionality of microarrays: Statistical challenges and (im)possible solutions
Stefan Michiels et al.
MOLECULAR ONCOLOGY (2011)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay et al.
BLOOD (2010)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
Microarray-Based Response Prediction in Esophageal Adenocarcinoma
Matthias Schauer et al.
CLINICAL CANCER RESEARCH (2010)
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
Charles J. David et al.
GENES & DEVELOPMENT (2010)
The Curse of Dimensionality: A Blessing to Personalized Medicine
Daniel R. Catchpoole et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma
Ariel Anguiano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Treatment of Multiple Myeloma: A Comprehensive Review
Robert A. Kyle et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
James R. Berenson et al.
ANNALS OF HEMATOLOGY (2008)
FIRMA: a method for detection of alternative splicing from exon array data
E. Purdom et al.
BIOINFORMATICS (2008)
Role of the NF-κB transcriptome and proteome as biomarkers in human head and neck squamous cell carcinomas
Zhong Chen et al.
BIOMARKERS IN MEDICINE (2008)
High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
Fenghuang Zhan et al.
BLOOD (2008)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer
Koichi Nagasaki et al.
BREAST CANCER (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Therese Sorlie et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Microarrays on gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand?
Eric H. Jensen et al.
CURRENT OPINION IN ONCOLOGY (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia
PZ Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection
C Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
